Pallisade Bio $PALI

$PALI was the biggest loser in the Prism MarketView Biotech index, finishing down 62% on the day after its Phase 2 Clinical Trial didn’t meet expectations

Share This Article

 

About the Author

Pallisade Bio $PALI

Joey Ramson